PRAME and neoplasm: In addition, silencing of PRAME reduced the frequency of CD8+ T cells with expression of the immune checkpoints PD‐1, LAG‐3 and VISTA, indicating that PRAME tumour expression considerably impairs the PD‐L1/PD‐1 axis by dysregulating both the ligand and receptor.